Gandalovičová Aneta, Rosel Daniel, Fernandes Michael, Veselý Pavel, Heneberg Petr, Čermák Vladimír, Petruželka Luboš, Kumar Sunil, Sanz-Moreno Victoria, Brábek Jan
Department of Cell Biology, Charles University, Viničná 7, Prague, Czech Republic; Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Průmyslová 595, 25242, Vestec u Prahy, Czech Republic.
Medbase, Chapel Hill, NC, USA.
Trends Cancer. 2017 Jun;3(6):391-406. doi: 10.1016/j.trecan.2017.04.008.
In solid cancers, invasion and metastasis account for more than 90% of mortality. However, in the current armory of anticancer therapies, a specific category of anti-invasion and antimetastatic drugs is missing. Here, we coin the term 'migrastatics' for drugs interfering with all modes of cancer cell invasion and metastasis, to distinguish this class from conventional cytostatic drugs, which are mainly directed against cell proliferation. We define actin polymerization and contractility as target mechanisms for migrastatics, and review candidate migrastatic drugs. Critical assessment of these antimetastatic agents is warranted, because they may define new options for the treatment of solid cancers.
在实体癌中,侵袭和转移导致的死亡率超过90%。然而,在目前的抗癌治疗手段中,缺少一类特定的抗侵袭和抗转移药物。在此,我们将干扰癌细胞所有侵袭和转移模式的药物称为“迁移抑制剂”,以将这类药物与主要针对细胞增殖的传统细胞生长抑制剂区分开来。我们将肌动蛋白聚合和收缩性定义为迁移抑制剂的作用靶点机制,并对候选迁移抑制药物进行综述。对这些抗转移药物进行批判性评估是必要的,因为它们可能为实体癌的治疗提供新的选择。